ChromaDex has developed a proprietary form of nicotinamide riboside (NR), a metabolic precursor of NAD+, which is a critical part of cellular functioning that declines with age. The company has conducted human clinical trials of its compound, showing that it increases NAD+ levels in humans, and it has been found to be safe by the FDA.
Further human clinical trials are underway, including in Alzheimer’s, Parkinson’s, chemo-induced peripheral neuropathy and arterial stiffness.
NR is the primary ingredient of ChromaDex’s flagship product, TRU NIAGEN.
